Blubell Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.75 Cr
- Revenue Growth -5.80%
- Profit Growth 69.08%
- Ebitda 90.20%
- Net Worth 161.85%
- Total Assets 13.11%
About Blubell Pharma
Blubell Pharma Private Limited (BPPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 June 2016 (Eight years and seven months 24 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.75 Cr.
Sangeet Dixit and Rajan Dhawan serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74999DL2016PTC301713
-
Company No.
301713
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
20 Jun 2016
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Blubell Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sangeet Dixit
|
Director | 20-Jun-2016 | Current |
|
Rajan Dhawan
|
Director | 20-Jun-2016 | Current |
Financial Performance of Blubell Pharma.
Blubell Pharma Private Limited, for the financial year ended 2021, experienced Minor drop in revenue, with a 5.8% decrease. The company also saw a substantial improvement in profitability, with a 69.08% increase in profit. The company's net worth Soared by an impressive increase of 161.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Blubell Pharma?
In 2021, Blubell Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Devbhoomi Pharmaceuticals Private LimitedSangeet Dixit and Rajan Dhawan are mutual person
-
Nee See Healthcare Private LimitedSangeet Dixit and Rajan Dhawan are mutual person
Charges (Loans)
₹17.50 M
₹0
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 1.75 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Mar 2020 | Axis Bank Limited | ₹1.75 Cr | Open |
How Many Employees Work at Blubell Pharma?
Unlock and access historical data on people associated with Blubell Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Blubell Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Blubell Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
